Zymergen

Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $ZY #investors--The Law Offices of Frank R. Cruz Continues Investigation of Zymergen Inc. (ZY) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Investigation of Zymergen Inc. (ZY) on Behalf of Investors

Zymergen Inc (NASDAQ: ZY) opened about 70% down in the stock market on Wednesday after the company said it expects no product revenue this year and immaterial product revenue in 2022. The nosedive slashed the biofacturing firm's market cap from over $3 billion when it went public in April to under $1 billion this morning.

Here's why Zymergen's stock is down 70% on Wednesday

BENSALEM, Pa.--(BUSINESS WIRE)---- $ZY #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) investors concerning the Company's possible violations of the federal securities laws. On August 3, 2021, after the market closed, Zymergen issued a business update stating that it “recently became aware of issues with its commercial product pipeline that will impact the Company's delivery timeline and revenue projections.” Specifically

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Zymergen Inc. (ZY) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)-- #ZY--Scott+Scott Attorneys at Law LLP Announces Investigation into Zymergen Inc. (ZY)

Scott+Scott Attorneys at Law LLP Announces Investigation into Zymergen Inc. (ZY)

The recently IPO'd synthetic biotechnology start-up ousts its CEO as its only product hits a brick wall.

Why Zymergen Stock Is Plunging 76% Today

The Ark Genomic Revolution ETF owned just over 1 million shares of Zymergen, leading to a loss of more than $26 million.

A recent IPO bought by Cathie Wood's Ark Invest just tanked 77% after it said product 'issues' will lead to little revenue this year and next

Boston, Massachusetts--(Newsfile Corp. - August 4, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations against Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY), a "biofacturing" company with headquarters in Emeryville, California. In April 2021, the Company completed its initial public offering ("IPO"). In the IPO, the Company sold approximately 18.5 million common shares at $31 per share.On August 3, 2021, after the market close,...

Berman Tabacco Investigates Potential Securities Claims Against Zymergen Inc. (ZY)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) investors concerning the Company's possible violations of the federal securities laws. On August 3, 2021, after the market closed, Zymergen issued a business update stating that it “recently became aware of issues with its commercial product pipeline that will impact the Company's delivery timeline and revenue projections.” As a result,

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors

New York, New York--(Newsfile Corp. - August 4, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Zymergen Inc. common stock (NASDAQ: ZY).Zymergen purports to design, develop, and commercialize breakthrough products faster, cheaper, and greener than before through what the company calls biofacturing. Zymergen held its initial public offering on April 21, 2021 and sold 18.54 million shares at $31.00 per share.Wolf Popper's investigation is focused on whether...

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Zymergen Inc. (ZY) Common Stock

LOS ANGELES--(BUSINESS WIRE)---- $ZY #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Zymergen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Zymergen Inc. (ZY) on Behalf of Investors

Zymergen reaffirmed product pipeline expectations in May. But ZY stock investors just received the bad news that the guidance no longer holds.

ZY Stock: Zymergen Plunges After Calling for No Product Revenue in 2021. Here's Why.

Zymergen Inc (NASDAQ:ZY) is trading significantly lower Wednesday morning after the company provided a business update regarding its commercial product pipeline and financial forecast. Zymergen announced that issues with its commercial product pipeline will impact its delivery timeline and revenue projections.

Why Zymergen Shares Are Getting Slammed Today

SAN DIEGO, Aug. 4, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Zymergen, Inc. (NASDAQ: ZY). On or about April 22, 2021, Zymergen sold about 16.3 million shares of stock in its initial public stock offering (the "IPO") at $31 a share, raising nearly $505 million in new capital.

Zymergen, Inc. (ZY) Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation

The stock price of Zymergen Inc (NASDAQ: ZY) fell by over 70% pre-market. This is why it happened.

ZY Stock Price Falls Over 70% Pre-Market: Why It Happened

Zymergen Inc (NASDAQ: ZY) shares continued to plummet in the pre-market trading on Tuesday. What's Moving?

Why Zymergen Stock Is Crashing Today

Three months after its IPO, Zymergen is warning investors that revenue is much further out than expected.

Synthetic biology company Zymergen plunges 68% after saying product revenue will be 'immaterial' in 2022, removing CEO

Atlanta, Georgia--(Newsfile Corp. - August 3, 2021) -  Holzer & Holzer, LLC is investigating whether Zymergen, Inc. ("Zymergen" or the "Company") (NASDAQ: ZY) complied with federal securities laws. On August 3, 2021, the Company provided a business update and revised its financial forecast. Specifically, the Company announced that it "recently became aware of issues with its commercial product pipeline that will impact the Company's delivery timeline and revenue projections. Accordingly, the Company no longer...

SHAREHOLDER ALERT: Investigation of Zymergen, Inc. Announced by Holzer & Holzer, LLC

Less than four months after going public and being valued at more than $3 billion by Wall Street, Zymergen Inc. unleashed some bad news Tuesday afternoon and was on pace to lose more than two-thirds of its market cap.

Fresh off IPO, ‘biofacturing' company Zymergen's stock plunges more than 70% after some really bad news

Apple

Alibaba

Virgin Galactic

Squarespace

Domino's Pizza

Skillsoft

Simply Good Foods

With the trading day more than halfway over, the markets were sliding. Each of the major indexes saw a loss at midday, with the Dow Jones industrial average leading the charge lower by 1%.

Alibaba, Apple, Squarespace, Virgin Galactic and More Tuesday Afternoon Analyst Calls

EMERYVILLE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming Goldman Sachs Annual Global Healthcare Virtual Conference.

Zymergen to Present at Goldman Sachs Annual Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that its portfolio company, Lodo Therapeutics Corporation ("Lodo" or the "Company"), has been acquired by Zymergen Inc. (NASDAQ: ZY) for an undisclosed amount. The transaction is the third exit from ALSP's investment fund, Accelerator Life Science Partners I (ALSP I), in the last year. Lodo Therapeutics discovered and developed novel therapeut

Accelerator Life Science Partners' Portfolio Company Lodo Therapeutics Acquired by Zymergen Inc.

SoftBank Group Corp

Coupang

DoorDash

NVIDIA

10X Genomics

Uber

Qualtrics International

Tech stocks are on display in Softbank's Vision Fund. These seven are among the best ones, now public, to consider investing in.

7 Best Tech Stocks Pumped Out by Softbank's ‘Golden Egg' Machine

AutoZone

Lordstown Motors

Here's a quick look at some earnings reports that were released after markets closed on Monday or before Tuesday's opening bell.

Earnings Hits and Misses: AutoZone, Lordstown Motors, Zymergen

Zymergen, Inc. (ZY) CEO Josh Hoffman on Q1 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world's leading biofacturing companies, today reported preliminary financial results for the first quarter ended March 31, 2021.

News for Zymergen Stock (ZY)